Amedeo Smart

Free Medical Literature Service

 

Amedeo

Autoimmune Disorders
  Free Subscription

Articles published in
J Neuroimmunol
    April 2024
  1. LI V, Binder MD, Purcell AW, Kilpatrick TJ, et al
    Antigen-specific immunotherapy via delivery of tolerogenic dendritic cells for multiple sclerosis.
    J Neuroimmunol. 2024;390:578347.
    >> Share

  2. MUNZ C
    Altered EBV specific immune control in multiple sclerosis.
    J Neuroimmunol. 2024;390:578343.
    >> Share

    March 2024
  3. LUO W, Wang X, Kong L, Chen H, et al
    Clinical features and prognosis of Tibetan patients with neuromyelitis optica spectrum disorder are different from those of Han Chinese patients.
    J Neuroimmunol. 2024;388:578263.
    >> Share

  4. KATSU M, Sekine-Tanaka M, Tanaka M, Horai Y, et al
    Inhibition of repulsive guidance molecule-a ameliorates compromised blood-spinal cord barrier integrity associated with neuromyelitis optica in rats.
    J Neuroimmunol. 2024;388:578297.
    >> Share

  5. HAHAM N, Zveik O, Rechtman A, Brill L, et al
    Altered immune co-inhibitory receptor expression and correlation of LAG-3 expression to disease severity in NMOSD.
    J Neuroimmunol. 2024;388:578289.
    >> Share

  6. DE ALMEIDA GMR, de Araujo RS, Castrillo BB, Silva GD, et al
    Therapeutic plasma exchange for neuromyelitis optica attacks: Evidence and challenges from a real-world cohort from Brazil.
    J Neuroimmunol. 2024;388:578295.
    >> Share

  7. CHANG EH, Hardy TA
    Peripheral oedema as an adverse effect of treatment of secondary progressive multiple sclerosis with siponimod: A case series.
    J Neuroimmunol. 2024;389:578330.
    >> Share

  8. FOGEL A, Olcer M, Goel A, Feng X, et al
    Novel biomarkers and interferon signature in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2024;389:578328.
    >> Share

    February 2024
  9. KMEZIC I, Press R, Glenewinkel H, Doppler K, et al
    Low-dose rituximab treatment in a patient with anti-neurofascin-155 IgG4 autoimmune nodopathy.
    J Neuroimmunol. 2024;389:578326.
    >> Share

  10. SRIWASTAVA S, Elkhooly M, Amatya S, Shrestha K, et al
    Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis.
    J Neuroimmunol. 2024;390:578315.
    >> Share

  11. ZHANG C, Liu R, Gao B, Li T, et al
    Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2024;387:578285.
    >> Share

  12. LOTFI A, Abbasi M, Karami N, Arghavanfar H, et al
    Effects of treadmill training on myelin proteomic markers and cerebellum morphology in a rat model of cuprizone-induced toxic demyelination.
    J Neuroimmunol. 2024;387:578286.
    >> Share

  13. SERAFINI B, Benincasa L, Rosicarelli B, Aloisi F, et al
    EBV infected cells in the multiple sclerosis brain express PD-L1: How the virus and its niche may escape immune surveillance.
    J Neuroimmunol. 2024;389:578314.
    >> Share

  14. FRID K, Usmann A, Markovits-Pachter T, Binyamin O, et al
    Granagard administration prolongs the survival of human mesenchymal stem cells transplanted into a mouse model of multiple sclerosis.
    J Neuroimmunol. 2024;389:578313.
    >> Share

  15. LI X, Chen JJ, Hur M, Paton GR, et al
    Papillitis associated with IgLON5 autoimmunity: A novel clinical phenotype.
    J Neuroimmunol. 2024;388:578312.
    >> Share

  16. TIAN J, Liu X, Liang H, Shen Y, et al
    Expression of lymphocyte activation gene-3 on CD4(+)T cells is regulated by cytokine interleukin-18 in myasthenia gravis.
    J Neuroimmunol. 2024;388:578308.
    >> Share

  17. GALETTA K, Ham AS, Vishnevetsky A, Bhattacharyya S, et al
    Disease modifying therapy in the treatment of tumefactive multiple sclerosis: A retrospective cohort study.
    J Neuroimmunol. 2024;388:578299.
    >> Share

    January 2024
  18. THAKOLWIBOON S, Linnoila J, Pittock SJ, Dubey D, et al
    Cerebellar leptomeningeal enhancement: An imaging finding of rapidly progressive Purkinje cell cytoplasmic autoantibody type 1 paraneoplastic cerebellar syndrome.
    J Neuroimmunol. 2024;387:578293.
    >> Share

  19. WADI L, Mandge V
    Electroconvulsive therapy for catatonia in anti-NMDA receptor encephalitis: A case series.
    J Neuroimmunol. 2024;386:578271.
    >> Share

  20. CERNE D, Losa M, Mattioli P, Lechiara A, et al
    Incident anti-LGI1 autoimmune encephalitis during dementia with Lewy bodies: when Occam razor is a double-edged sword.
    J Neuroimmunol. 2024;387:578291.
    >> Share

  21. PETERSEN-CHERUBINI CL, Liu Y, Deffenbaugh JL, Murphy SP, et al
    Dysregulated autotaxin expression by T cells in multiple sclerosis.
    J Neuroimmunol. 2024;387:578282.
    >> Share

  22. FUJIMORI J, Nakashima I
    Early-stage volume losses in the corpus callosum and thalamus predict the progression of brain atrophy in patients with multiple sclerosis.
    J Neuroimmunol. 2024;387:578280.
    >> Share

    December 2023
  23. BAEVA ME, Tottenham I, Koch M, Camara-Lemarroy C, et al
    Biomarkers of disability worsening in inactive primary progressive multiple sclerosis.
    J Neuroimmunol. 2023;387:578268.
    >> Share

  24. STAVROGIANNI K, Kitsos DK, Giannopapas V, Chasiotis AK, et al
    Neuropsychological profiles comparison between Multiple Sclerosis patients and Multiple Sclerosis patients with overlapping features of Systemic Lupus Erythematosus.
    J Neuroimmunol. 2023;387:578270.
    >> Share

  25. LI HY, Xia M, Song M, Xie Y, et al
    Rs1800629 polymorphism in TNF-alpha is associated with the susceptibility and initial short-term glucocorticoids efficacy in myasthenia gravis patients.
    J Neuroimmunol. 2023;387:578269.
    >> Share

  26. HU B, Dang G, Chen S, Li S, et al
    Neuromyelitis optica spectrum disorder mimicking stroke: A case report and literature review.
    J Neuroimmunol. 2023;385:578223.
    >> Share

  27. MIYAZAWA R, Fujimori J, Atobe Y, Nakashima I, et al
    CSF CXCL13 is elevated in patients with CIDP and may reflect higher disease activity.
    J Neuroimmunol. 2023;385:578238.
    >> Share

  28. TESFAGIORGIS Y, Kemal EA, Craig HC, Parham KA, et al
    Systemic administration of anti-CD20 indirectly reduces B cells in the inflamed meninges in a chronic model of central nervous system autoimmunity.
    J Neuroimmunol. 2023 Dec 15:578267. doi: 10.1016/j.jneuroim.2023.578267.
    >> Share

    November 2023
  29. CHEN Y, Wan W, Yao X, Guan Y, et al
    Drug-drug interaction between paxlovid and tacrolimus in a patient with myasthenia gravis and SARS-CoV-2 infection.
    J Neuroimmunol. 2023;385:578245.
    >> Share

  30. LOWE MC, Money KM, Matthews E, Pastula DM, et al
    case of autoimmune GFAP astrocytopathy with eosinophils in the cerebrospinal fluid.
    J Neuroimmunol. 2023;385:578249.
    >> Share

  31. CAO B, Li Q, Xiong L, Ruan H, et al
    Cerebrospinal fluid uric acid levels associated with disease severity in patients with anti-N-methyl-d-aspartate receptor encephalitis.
    J Neuroimmunol. 2023;384:578221.
    >> Share

  32. LI Y, Liu Y, Zhao W, An X, et al
    Serum neurofilament light chain predicts spinal cord atrophy in neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2023;384:578218.
    >> Share

  33. YASUDA M, Uzawa A, Kuwabara S, Suzuki S, et al
    Clinical features and outcomes of patients with muscle-specific kinase antibody-positive myasthenia gravis in Japan.
    J Neuroimmunol. 2023;385:578241.
    >> Share

  34. FARAJI J, Bettenson D, Yong VW, Metz GAS, et al
    Early life stress aggravates disease pathogenesis in mice with experimental autoimmune encephalomyelitis: Support for a two-hit hypothesis of multiple sclerosis etiology.
    J Neuroimmunol. 2023;385:578240.
    >> Share

    October 2023
  35. LEAL RATO M, Santos M, de Sa J, Ferreira J, et al
    Comorbid autoimmune disorders in people with multiple sclerosis: A retrospective cohort study.
    J Neuroimmunol. 2023;385:578226.
    >> Share

  36. MOORE L, Munir A, Bae S, Miller J, et al
    Transverse myelitis associated with Mpox infection.
    J Neuroimmunol. 2023;383:578190.
    >> Share

  37. KORAL G, Ulusoy C, Cossins J, Lazaridis K, et al
    Silencing of FCRLB by shRNA ameliorates MuSK-induced EAMG in mice.
    J Neuroimmunol. 2023;383:578195.
    >> Share

  38. RASHED HR, Niu Z, Dyck PJ, Dyck PJB, et al
    Nerve transcriptomes in autoimmune and genetic demyelinating neuropathies: Pathogenic pathway assessment of nerve demyelination.
    J Neuroimmunol. 2023;384:578220.
    >> Share

  39. KIM KW, Ljunggren-Rose A, Matta P, Toki S, et al
    Inhibition of SUMOylation promotes remyelination and reduces IL-17 mediated autoimmune inflammation: Novel approach toward treatment of inflammatory CNS demyelinating disease.
    J Neuroimmunol. 2023;384:578219.
    >> Share

    September 2023
  40. DOMINGUEZ L, McKeon A, Tobin WO, Lopez-Chiriboga S, et al
    Long term outcomes in patients with anti-DPPX autoimmunity.
    J Neuroimmunol. 2023;384:578214.
    >> Share

  41. HOLM-YILDIZ S, Dysgaard T, Krag T, Pedersen BS, et al
    Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis.
    J Neuroimmunol. 2023;384:578215.
    >> Share

  42. YASUDA M, Uzawa A, Ozawa Y, Kojima Y, et al
    Serum cytokine profiles in myasthenia gravis with anti-muscle-specific kinase antibodies.
    J Neuroimmunol. 2023;384:578205.
    >> Share

  43. CHENG X, Li Y, Wang Y, Sun Y, et al
    Impact of blood-brain barrier disruption on clinical features and treatment response in patients with newly diagnosed autoimmune encephalitis.
    J Neuroimmunol. 2023;383:578203.
    >> Share

  44. ROSHAN HM, Valadan R, Hosseini SA, Ajami A, et al
    Specific antibodies to EBNA1 epitopes as risk factors for multiple sclerosis, a systematic review.
    J Neuroimmunol. 2023;383:578202.
    >> Share

  45. CHHABRA S, Mehan S, Khan Z, Gupta GD, et al
    Matrine mediated neuroprotective potential in experimental multiple sclerosis: Evidence from CSF, blood markers, brain samples and in-silico investigations.
    J Neuroimmunol. 2023;384:578200.
    >> Share

  46. MICHAEL MR, Wieske L, Koel-Simmelink MJ, van Schaik IN, et al
    Serum B-cell activating factor is not a potential biomarker for disease activity in chronic inflammatory demyelinating polyneuropathy.
    J Neuroimmunol. 2023;382:578169.
    >> Share

  47. YAMAHARA N, Yoshikura N, Takekoshi A, Kimura A, et al
    Anti-N-methyl-d-aspartate receptor encephalitis preceded by meningitis lasting up to 60 days.
    J Neuroimmunol. 2023;382:578173.
    >> Share

  48. NI J, Liu X, Zhang R, Wang H, et al
    Systemic administration of Shikonin ameliorates cognitive impairment and neuron damage in NPSLE mice.
    J Neuroimmunol. 2023;382:578166.
    >> Share

  49. HUANG Z, Liu Y, An X, Zhang C, et al
    Rituximab induces a transient fluctuation of peripheral and follicular helper T cells in neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2023;382:578167.
    >> Share

  50. ERLEBACH R, Brandi G
    Effect and timing of operative treatment for teratoma associated N-Methyl-d-Aspartate receptor-antibody encephalitis: A systematic review with meta-analysis.
    J Neuroimmunol. 2023;382:578153.
    >> Share

  51. GELIBTER S, Pirro F, Saraceno L, Susani E, et al
    Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
    J Neuroimmunol. 2023;383:578199.
    >> Share

  52. PERDAENS O, van Pesch V
    MicroRNAs are dysregulated in peripheral blood mononuclear cells in multiple sclerosis and correlate with T cell mediators.
    J Neuroimmunol. 2023;386:578196.
    >> Share

    August 2023
  53. KHAN E, Kagzi Y, Elkhooly M, Surpur S, et al
    Disease modifying therapy and pregnancy outcomes in multiple sclerosis: A systematic review and meta-analysis.
    J Neuroimmunol. 2023;383:578178.
    >> Share

  54. BALAZS I, Horvath A, Heschl B, Khalil M, et al
    Anti-CD20 treatment and neutrophil function in central nervous system demyelinating diseases.
    J Neuroimmunol. 2023;381:578136.
    >> Share

  55. LI J, Wang Y, Xia R, Zhao X, et al
    Elevated cerebrospinal fluid YKL-40 levels in patients with anti-gamma-aminobutyric- acid-B receptor encephalitis.
    J Neuroimmunol. 2023;381:578119.
    >> Share

  56. TERRIM S, Silva GD, de Sa E Benevides Falcao FC, Dos Reis Pereira C, et al
    Real-world application of the 2022 diagnostic criteria for first-ever episode of optic neuritis.
    J Neuroimmunol. 2023;381:578140.
    >> Share

  57. RUNGE K, Rauer S, Waibel E, Nickel K, et al
    Steroid-responsive encephalopathy associated with autoimmune thyroiditis presenting as cortisone sensible psychosis with reversible leukoencephalopathy.
    J Neuroimmunol. 2023;382:578177.
    >> Share

  58. SOTTINI A, Quaresima V, Barbaro M, Moiola L, et al
    Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab.
    J Neuroimmunol. 2023;382:578170.
    >> Share

  59. BRUNE-INGEBRETSEN S, Hogestol EA, de Rosbo NK, Berg-Hansen P, et al
    Immune cell subpopulations and serum neurofilament light chain are associated with increased risk of disease worsening in multiple sclerosis.
    J Neuroimmunol. 2023;382:578175.
    >> Share

  60. ZHANG JR, Zhuang S, Xu XD, Song WL, et al
    Overlapping Epstein-Barr virus encephalitis and autoimmune glial fibrillary acidic protein astrocytopathy.
    J Neuroimmunol. 2023;382:578174.
    >> Share

  61. LI T, Li X, Hong S, Jiang L, et al
    Clinical characteristics of autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy in children: A case series of 16 patients.
    J Neuroimmunol. 2023;382:578176.
    >> Share

    July 2023
  62. ADAMEC I, Brecl Jakob G, Rajda C, Drulovic J, et al
    Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers.
    J Neuroimmunol. 2023;382:578164.
    >> Share

  63. YAO X, Zhang C, Zhang Y, Geng J, et al
    Amphiphysin-IgG autoimmune sciatic neuropathy and facial neuropathy related to primary central nervous system lymphoma: A case report.
    J Neuroimmunol. 2023;382:578156.
    >> Share

  64. SERIZAWA K, Miyake S, Katsura Y, Yorozu K, et al
    Intradermal AQP4 peptide immunization induces clinical features of neuromyelitis optica spectrum disorder in mice.
    J Neuroimmunol. 2023;380:578109.
    >> Share

  65. PRIEGO M, Noriega L, Kalinin S, Hoffman LM, et al
    Genetic deletion of c-Jun amino-terminal kinase 3 (JNK3) modestly increases disease severity in a mouse model of multiple sclerosis.
    J Neuroimmunol. 2023;382:578152.
    >> Share

  66. WANG R, Sun DR, Du Q, Zhang Y, et al
    Serum antinuclear antibodies associate with severe disease activity in neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2023;382:578151.
    >> Share

    June 2023
  67. HAWES IA, Alvarenga BD, Browne W, Wapniarski A, et al
    Viral co-infection, autoimmunity, and CSF HIV antibody profiles in HIV central nervous system escape.
    J Neuroimmunol. 2023;381:578141.
    >> Share

  68. ELKJAER ML, Lohse RM, Burton M, Mendoza JP, et al
    Whole blood miRNAs in relapsing MS patients treated with dimethyl fumarate in the phase 4 TREMEND trial.
    J Neuroimmunol. 2023;381:578145.
    >> Share

  69. SI W, Ni Y, Jiang Q, Tan L, et al
    Nanopore sequencing identifies differentially methylated genes in the central nervous system in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2023;381:578134.
    >> Share

  70. BLASK C, Schulze J, Rumpel S, Susse M, et al
    Modulation of cytokine release from peripheral blood mononuclear cells from multiple sclerosis patients by coenzyme A and soraphen A.
    J Neuroimmunol. 2023;381:578135.
    >> Share

  71. CARIA P, Pilotto S, D'Alterio MN, Fronza M, et al
    Leukocyte telomere length in women with multiple sclerosis: Comparison with healthy women during pregnancy and puerperium.
    J Neuroimmunol. 2023;381:578137.
    >> Share

  72. MICHETTI L, Maffina F, Ravasio R, Barcella V, et al
    Free light chains as a reliable biomarker of intrathecal synthesis in the diagnosis of CNS inflammatory diseases.
    J Neuroimmunol. 2023;379:578091.
    >> Share

  73. CEBI M, Cakar A, Erdogdu E, Durmus-Tekce H, et al
    Thymoma patients with or without myasthenia gravis have increased Th17 cells, IL-17 production and ICOS expression.
    J Neuroimmunol. 2023;381:578129.
    >> Share

  74. EL MAHDAOUI S, Husted SR, Hansen MB, Cobanovic S, et al
    Cerebrospinal fluid soluble CD27 is associated with CD8(+) T cells, B cells and biomarkers of B cell activity in relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2023;381:578128.
    >> Share

    May 2023
  75. MARSTERS C, Nathoo N, Amatto L, Wong R, et al
    Normocomplementemic urticarial vasculitis in a patient with multiple sclerosis on glatiramer acetate.
    J Neuroimmunol. 2023;380:578110.
    >> Share

  76. ABOSEIF A, Toljan K, Mahadeen A, Zeft A, et al
    Pediatric anti-NMDA-receptor autoimmune encephalitis in siblings: Developmental, Electrophysiologic, and Genetic Implications.
    J Neuroimmunol. 2023;379:578107.
    >> Share

  77. TAKEGAMI N, Sakuishi K, Yamaguchi-Takegami N, Egashira S, et al
    Anti-Lactosylceramide antibody positive combined central peripheral demyelination emerging from long-standing juvenile-onset chronic inflammatory polyradiculoneuropathy; a report of two cases.
    J Neuroimmunol. 2023;378:578086.
    >> Share

  78. GE A, Sun Y, Kiker T, Zhou Y, et al
    A metabolome-wide Mendelian randomization study prioritizes potential causal circulating metabolites for multiple sclerosis.
    J Neuroimmunol. 2023;379:578105.
    >> Share

  79. MANZANO GS, Rice DR, Zurawski J, Jalkh Y, et al
    Familial Mediterranean Fever and multiple sclerosis treated with ocrelizumab: Case report.
    J Neuroimmunol. 2023;379:578099.
    >> Share

  80. XUE Y, Zhang L, Guo R, Shao X, et al
    miR-485 regulates Th17 generation and pathogenesis in experimental autoimmune encephalomyelitis through targeting STAT3.
    J Neuroimmunol. 2023;379:578100.
    >> Share

    April 2023
  81. MO Y, Wang S, Chang Y, Sun X, et al
    A novel rare variant of CNPY3 from familial NMOSD impairs the TLR-mediated immune response.
    J Neuroimmunol. 2023;377:578065.
    >> Share

  82. MULLER-MINY L, Heming M, Lautwein T, Ruck T, et al
    Alemtuzumab treatment exemplifies discordant immune effects of blood and cerebrospinal fluid in multiple sclerosis.
    J Neuroimmunol. 2023;378:578088.
    >> Share

  83. VACARAS V, Muresanu DF, Buzoianu AD, Nistor C, et al
    The role of multiple sclerosis therapies on the dynamic of human gut microbiota.
    J Neuroimmunol. 2023;378:578087.
    >> Share

  84. WANG H, Yi B, Wang M, Wang Y, et al
    Cerebellar ataxia with anti-mGluR1 auto-antibody in a pediatric patient: A case report.
    J Neuroimmunol. 2023;378:578082.
    >> Share

    March 2023
  85. ABBADESSA G, Miele G, Cavalla P, Valentino P, et al
    Previous disease-modifying treatments influence T lymphocyte kinetics in people with multiple sclerosis switching to ocrelizumab.
    J Neuroimmunol. 2023;378:578072.
    >> Share

  86. DINOTO A, Zara P, Mariotto S, Ferrari S, et al
    Autoimmune encephalitis misdiagnosis and mimics.
    J Neuroimmunol. 2023;378:578071.
    >> Share

  87. HOWARTH R, Blackwell L, Gombolay G
    Assessment of cognitive status in pediatric anti-NMDA receptor encephalitis during inpatient rehabilitation: A retrospective cohort.
    J Neuroimmunol. 2023;376:578048.
    >> Share

  88. FERREIRA F, Ferreira D, Guimaraes J, Soares-Dos-Reis R, et al
    Recurrent encephalopathy associated with pegylated beta-interferon treatment.
    J Neuroimmunol. 2023;376:578037.
    >> Share

  89. GOU B, Yang P, Feng J, Li Y, et al
    The case report of AQP4 and MOG IgG double positive NMOSD treated with subcutaneous Ofatumumab.
    J Neuroimmunol. 2023;376:578035.
    >> Share

  90. HEBER M, Li Y
    Caution on LRP4 antibody results in patients being evaluated for myasthenia gravis.
    J Neuroimmunol. 2023;377:578063.
    >> Share

  91. PALACIO PL, Pleet ML, Reategui E, Magana SM, et al
    Emerging role of extracellular vesicles in multiple sclerosis: From cellular surrogates to pathogenic mediators and beyond.
    J Neuroimmunol. 2023;377:578064.
    >> Share

  92. ZHOU Q, Yin D, Ma J, Chen S, et al
    The therapeutic effect of ofatumumab in autoimmune encephalitis: A case series.
    J Neuroimmunol. 2023;377:578062.
    >> Share

    January 2023
  93. SERAFINI B, Rosicarelli B, Veroni C, Aloisi F, et al
    Tissue-resident memory T cells in the multiple sclerosis brain and their relationship to Epstein-Barr virus infected B cells.
    J Neuroimmunol. 2023;376:578036.
    >> Share

  94. GARDNER AM, Atkinson JR, Wilkinson NM, Jerome AD, et al
    TAM receptor signaling dictates lesion location and clinical phenotype during experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2023;375:578016.
    >> Share

  95. LI K, Hou L, Tan Y, Huang Y, et al
    Iron metabolism in non-anemic myasthenia gravis patients: A cohort study.
    J Neuroimmunol. 2023;375:578015.
    >> Share

  96. AKAMINE H, Uzawa A, Kojima Y, Ozawa Y, et al
    Role of soluble forms of follicular helper T-cell membrane molecules in the pathogenesis of myasthenia gravis.
    J Neuroimmunol. 2023;375:578014.
    >> Share

    December 2022
  97. MCCOMBE JA, Zivelonghi C, Vorasoot N, Majed M, et al
    AMPAR autoimmunity: Neurological and oncological accompaniments and co-existing neural autoantibodies.
    J Neuroimmunol. 2022;375:578012.
    >> Share

  98. HARAHSHEH E, Callister M, Hasan S, Gritsch D, et al
    Aquaporin-4 IgG neuromyelitis optica spectrum disorder onset after Covid-19 vaccination: Systematic review.
    J Neuroimmunol. 2022;373:577994.
    >> Share

  99. ENDRES D, Frye BC, Schlump A, Kuzior H, et al
    Sarcoidosis and obsessive-compulsive symptoms.
    J Neuroimmunol. 2022;373:577989.
    >> Share

  100. CANISSARIO R, Samkoff L, Jean MJ, Williams Z, et al
    GFAP astrocytopathy presenting with profound intracranial hypertension and vision loss.
    J Neuroimmunol. 2022;373:577976.
    >> Share

  101. CURRAN C, Vaitaitis G, Waid D, Volmer T, et al
    Ocrevus reduces TH40 cells, a biomarker of systemic inflammation, in relapsing multiple sclerosis (RMS) and in progressive multiple sclerosis (PMS).
    J Neuroimmunol. 2022;374:578008.
    >> Share

    November 2022
  102. EATON J, Rahmlow M
    Myelin oligodendrocyte glycoprotein associated transverse myelitis following brain abscess: Case report and literature review.
    J Neuroimmunol. 2022;372:577967.
    >> Share

  103. SHU Y, Ma X, Chen C, Wang Y, et al
    Myelin oligodendrocyte glycoprotein-associated disease is associated with BANK1, RNASET2 and TNIP1 polymorphisms.
    J Neuroimmunol. 2022;372:577937.
    >> Share

    October 2022
  104. LI X, Chu Y, Ma R, Dou M, et al
    Ferroptosis as a mechanism of oligodendrocyte loss and demyelination in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2022;373:577995.
    >> Share

  105. CUTELLE C, Balducci C, Cereda D, Fusco ML, et al
    K index utility as diagnostic and prognostic biomarker in the assessment of patients with suspected Multiple Sclerosis.
    J Neuroimmunol. 2022;373:577992.
    >> Share

  106. DE SOUZA TIEPPO EM, da Silva TFF, de Araujo RS, Silva GD, et al
    Primary angiitis of the central nervous system as a mimic of multiple sclerosis: A case report.
    J Neuroimmunol. 2022;373:577991.
    >> Share

  107. BEECHER G, Howe BM, Shelly S, Staff NP, et al
    Plexus MRI helps distinguish the immune-mediated neuropathies MADSAM and MMN.
    J Neuroimmunol. 2022;371:577953.
    >> Share

  108. FEIZI P, Sharma K, Pasham SR, Nirwan L, et al
    Central nervous system (CNS) inflammatory demyelinating diseases (IDDs) associated with COVID-19: A case series and review.
    J Neuroimmunol. 2022;371:577939.
    >> Share

  109. VERGOOSSEN DLE, Ruiter AM, Keene KR, Niks EH, et al
    Enrichment of serum IgG4 in MuSK myasthenia gravis patients.
    J Neuroimmunol. 2022;373:577978.
    >> Share

    September 2022
  110. FARAJI J, Gustafson C, Bettenson D, Negoro H, et al
    Bladder dysfunction in experimental autoimmune encephalomyelitis reflects clinical severity: A pilot study.
    J Neuroimmunol. 2022;372:577973.
    >> Share

  111. LAMBE J, McGinley MP, Moss BP, Mao-Draayer Y, et al
    Myelin oligodendrocyte glycoprotein-IgG associated disorders (MOGAD) following SARS-CoV-2 infection: A case series.
    J Neuroimmunol. 2022;370:577933.
    >> Share

  112. KASHYAP N, Morris M, Loerinc LB, Benoit M, et al
    The neutrophil-to-lymphocyte ratio is associated with intubation in pediatric anti-NMDA receptor encephalitis: A retrospective study.
    J Neuroimmunol. 2022;370:577931.
    >> Share

  113. KELLY H, Johnson J, Jakubecz C, Serra A, et al
    Prevalence of iatrogenic CNS inflammation at a tertiary neuroimmunology clinic.
    J Neuroimmunol. 2022;370:577928.
    >> Share

  114. HARAMATI A, Rechtman A, Zveik O, Haham N, et al
    IL-6 as a marker for NMOSD disease activity.
    J Neuroimmunol. 2022;370:577925.
    >> Share

  115. MAGALASHVILI D, Mandel M, Dreyer-Alster S, Didikin M, et al
    Cladribine treatment for highly active multiple sclerosis: Real-world clinical outcomes for years 3 and 4.
    J Neuroimmunol. 2022;372:577966.
    >> Share

    August 2022
  116. WU H, Chen L, Zhou X, Wu Y, et al
    Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis.
    J Neuroimmunol. 2022;372:577955.
    >> Share

  117. ORTIGOZA-ESCOBAR JD, Fernandez de Sevilla M, Monfort L, Anton J, et al
    Cytokine profile and brain biopsy in a case of childhood-onset central nervous system vasculitis in Noonan syndrome-like disorder due to a novel CBL variant.
    J Neuroimmunol. 2022;369:577917.
    >> Share

  118. JIANG W, Sun X, Huang H, Sun H, et al
    Bilateral parafalcine cortical and leptomeningeal impairment in MOG antibody disease and AQP4 neuromyelitis optica.
    J Neuroimmunol. 2022;369:577898.
    >> Share

  119. NEWSOME SD, Johnson T
    Stiff person syndrome spectrum disorders; more than meets the eye.
    J Neuroimmunol. 2022;369:577915.
    >> Share

  120. GALASSI G
    Comment on "SARS-CoV-2 vaccinations may not only be complicated by GBS but also by distal small fiber neuropathy by J. Finsterer.
    J Neuroimmunol. 2022;369:577901.
    >> Share

  121. CAO B, Luo M, Li J, Lu Y, et al
    Cerebrospinal fluid cystatin C levels in patients with anti-NMDAR encephalitis and other neurological diseases.
    J Neuroimmunol. 2022;369:577900.
    >> Share

  122. RACKE MK, Batish SD, Lisak RP, Barohn RJ, et al
    LRP4 antibody testing in myasthenia gravis.
    J Neuroimmunol. 2022;371:577949.
    >> Share

  123. ISHIZUCHI K, Takizawa T, Ohnuki Y, Sekiguchi K, et al
    Immunodeficiency in patients with thymoma-associated myasthenia gravis.
    J Neuroimmunol. 2022;371:577950.
    >> Share

    July 2022
  124. ALOISI F, Cross AH
    MINI-review of Epstein-Barr virus involvement in multiple sclerosis etiology and pathogenesis.
    J Neuroimmunol. 2022;371:577935.
    >> Share

  125. FUCHS L, Mausner-Fainberg K, Luban A, Asseyer SE, et al
    CTGF/CCN2 has a possible detrimental role in the inflammation and the remyelination failure in the early stages of multiple sclerosis.
    J Neuroimmunol. 2022;371:577936.
    >> Share

  126. MURAKAMI K, Miyamoto K, Terayama A, Yoshikawa K, et al
    Acute eye movement-retained internal ophthalmoplegia in atypical Miller Fisher syndrome variants are associated with IgG anti-GQ1b antibodies.
    J Neuroimmunol. 2022;368:577880.
    >> Share

  127. DAS NEVES SP, Serre-Miranda C, Sousa JC, Costa PS, et al
    Lipocalin-2 does not influence EAE clinical score but it increases inflammation in central nervous system.
    J Neuroimmunol. 2022;368:577872.
    >> Share

  128. VAN DER WEELE L, Pollastro S, van Schaik BDC, van Kampen AHC, et al
    Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif) using B cell receptor repertoire analysis.
    J Neuroimmunol. 2022;370:577932.
    >> Share

  129. FONAGER SV, Winther G, Wittenborn TR, Jensen L, et al
    Increased maternofoetal transfer of antibodies in a murine model of systemic lupus erythematosus, but no immune activation and neuroimmune sequelae in offspring.
    J Neuroimmunol. 2022;370:577927.
    >> Share

  130. KASHEKE GDS, Holman SP, Robertson GS
    Fingolimod attenuates gait deficits in mice subjected to experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2022;370:577926.
    >> Share

  131. STRIJBOS E, van Ostaijen-Ten Dam MM, Vervat C, Schilham MW, et al
    The effect of immunosuppression or thymectomy on the response to tetanus revaccination in myasthenia gravis.
    J Neuroimmunol. 2022;370:577930.
    >> Share

    June 2022
  132. WEIHUA Z, Haitao R, Jie D, Changhong R, et al
    Autoimmune cerebellar ataxia associated with anti-leucine-rich glioma-inactivated protein 1 antibodies: Two pediatric cases.
    J Neuroimmunol. 2022;370:577918.
    >> Share

  133. RACKE MK, Niles JK, Lorenz RA, Kaufman HW, et al
    Changes in ganglioside antibody positivity rates during the COVID-19 pandemic.
    J Neuroimmunol. 2022;367:577877.
    >> Share

  134. NIE DA, Abud A, Serrano-Gonzalez M, Harappanahally G, et al
    Pediatric stiff limb syndrome with polyautoimmunity of anti-GAD-65, anti-islet cell, and thyroid peroxidase antibodies: A case report and review of literature.
    J Neuroimmunol. 2022;367:577865.
    >> Share

  135. MASI G, Li Y, Karatz T, Pham MC, et al
    The clinical need for clustered AChR cell-based assay testing of seronegative MG.
    J Neuroimmunol. 2022;367:577850.
    >> Share

  136. HU K, Yang Y, Liu J, Chen X, et al
    Susac syndrome with the typical clinical triad: A case report and literature review.
    J Neuroimmunol. 2022;367:577822.
    >> Share

  137. YAO Y, Zhang O, Gu L, Zhang X, et al
    Analysis of risk factors for a poor functional prognosis and relapse in patients with autoimmune encephalitis.
    J Neuroimmunol. 2022;369:577899.
    >> Share

  138. CHAN F, Riminton DS, Ramanathan S, Reddel SW, et al
    Distinguishing CNS neurosarcoidosis from multiple sclerosis and an approach to "overlap" cases.
    J Neuroimmunol. 2022;369:577904.
    >> Share

    May 2022
  139. YAO Y, Uddin MN, Manley K, Lawrence DA, et al
    Improvements of autism-like behaviors but limited effects on immune cell metabolism after mitochondrial replacement in BTBR T(+)Itpr3(tf)/J mice.
    J Neuroimmunol. 2022;368:577893.
    >> Share

  140. KLEIN CJ, Beecher G, Lamb C, Naddaf E, et al
    LRP4-IgG service line testing in seronegative myasthenia gravis and controls.
    J Neuroimmunol. 2022;368:577895.
    >> Share

  141. PAUL SA, Roy D, Mondal GP, Bhattacharyya R, et al
    Primary angiitis of central nervous system - A challenging diagnosis.
    J Neuroimmunol. 2022;366:577844.
    >> Share

  142. DINOTO A, McKeon A, Vattemi G, Carta S, et al
    Neuronal intermediate filament paraneoplastic autoimmunity complicating avelumab therapy of Merkel cell carcinoma.
    J Neuroimmunol. 2022;368:577882.
    >> Share

  143. GILL AJ, Venkatesan A
    Pathogenic mechanisms in neuronal surface autoantibody-mediated encephalitis.
    J Neuroimmunol. 2022;368:577867.
    >> Share

    April 2022
  144. WANG J, Jin L, Zhang X, Yu H, et al
    Activated microglia by (18)F-DPA714 PET in a case of anti-LGI1 autoimmune encephalitis.
    J Neuroimmunol. 2022;368:577879.
    >> Share

  145. FERILLI MAN, Papi C, Sabatelli M, Colosimo C, et al
    MOG autoimmunity mimicking CLIPPERS syndrome: Case report and literature review.
    J Neuroimmunol. 2022;367:577875.
    >> Share

  146. MA R, Chu Y, Dou M, Jing Y, et al
    Matrine inhibits the Wnt3a/beta-catenin/TCF7L2 signaling pathway in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2022;367:577876.
    >> Share

  147. KYLLESBECH C, Trier N, Slibinskas R, Ciplys E, et al
    Virus-specific antibody indices may supplement the total IgG index in diagnostics of multiple sclerosis.
    J Neuroimmunol. 2022;367:577868.
    >> Share

  148. ODA F, Uzawa A, Ozawa Y, Yasuda M, et al
    Serum cytokine and chemokine profiles in patients with immune-mediated necrotizing myopathy.
    J Neuroimmunol. 2022;365:577833.
    >> Share

  149. DEKEYSER C, Naesens L, Offner F, De Vriendt C, et al
    A unique phenotype of longitudinal extensive transverse myelitis in autoimmune lymphoproliferative syndrome.
    J Neuroimmunol. 2022;367:577866.
    >> Share

  150. MCKEON-MAKKI I, McKeon A, Yang B, Pittock SJ, et al
    Adenylate kinase 5 (AK5) autoimmune encephalitis: Clinical presentations and outcomes in three new patients.
    J Neuroimmunol. 2022;367:577861.
    >> Share

    March 2022
  151. JIN J, Shneyderman M, Smith MD, Gharagozloo M, et al
    Retinal pathology in spontaneous opticospinal experimental autoimmune encephalitis mice.
    J Neuroimmunol. 2022;367:577859.
    >> Share

  152. TOTTENHAM I, Koch M, Camara-Lemarroy C
    Serum HGF and APN2 are associated with disability worsening in SPMS.
    J Neuroimmunol. 2022;364:577803.
    >> Share

  153. NEPAL G, Kharel S, Coghlan MA, Rayamajhi P, et al
    Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis.
    J Neuroimmunol. 2022;364:577812.
    >> Share

  154. WENG J, Du Z, Zhang Y
    CNS limited ANCA-associated vasculitis presenting as an isolated intraparenchymal mass.
    J Neuroimmunol. 2022;364:577791.
    >> Share

  155. DIAZ P, Leveque M, Hautecloque G, Sellal F, et al
    The challenge of diagnosing Guillain-Barre syndrome in patients with COVID-19 in the intensive care unit.
    J Neuroimmunol. 2022;366:577842.
    >> Share

  156. SALARI AA, Jand Y, Ghazi-Khansari M
    Antibiotic treatment during pregnancy and lactation in dams exacerbates clinical symptoms and inflammatory responses in offspring with experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2022;366:577840.
    >> Share

    February 2022
  157. MA J, Yu H, Wang H, Zhang X, et al
    Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    J Neuroimmunol. 2022;363:577790.
    >> Share

  158. COSTA D, Sardoeira A, Carneiro P, Neves E, et al
    Autoimmune encephalitis: suspicion in clinical practice and mimics.
    J Neuroimmunol. 2022;365:577824.
    >> Share

    January 2022
  159. MOLLER L, Kerwat M, Timmermann L, Simon OJ, et al
    When your cat takes you to the ICU: Miller Fisher/ Guillain-Barre-overlap-syndrome caused by Pasteurella multocida infection resembling wound botulism.
    J Neuroimmunol. 2022;365:577821.
    >> Share

  160. ISMAIL II, Salama S
    A systematic review of cases of CNS demyelination following COVID-19 vaccination.
    J Neuroimmunol. 2022;362:577765.
    >> Share

  161. MA X, Chen C, Fang L, Zhong X, et al
    Dysregulated CD40 and CD40 ligand expression in anti-N-methyl-d-aspartate receptor encephalitis.
    J Neuroimmunol. 2022;362:577762.
    >> Share

  162. KADISH R, Clardy SL, Royston M, Tanvir I, et al
    Clinical burden of relapses in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder: A single center cohort analysis.
    J Neuroimmunol. 2022;362:577761.
    >> Share

  163. KALININ S, Boullerne AI, Feinstein DL
    Serum levels of lipocalin-2 are elevated at early times in African American relapsing remitting multiple sclerosis patients.
    J Neuroimmunol. 2022;364:577810.
    >> Share

  164. YE F, Dai Y, Wang T, Liang J, et al
    Trans-omics analyses revealed key epigenetic genes associated with overall survival in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2022;364:577809.
    >> Share

  165. BRORSON IS, Eriksson AM, Hogestol E, Leikfoss IS, et al
    Global DNA methylation changes in treated and untreated MS patients measured over time.
    J Neuroimmunol. 2022;364:577808.
    >> Share

  166. URRIOLA N, Blazek K, Adelstein S
    Subunit-specific autoantibodies in autoimmune autonomic ganglionopathy.
    J Neuroimmunol. 2022;363:577805.
    >> Share

    December 2021
  167. RONCHI NR, Silva GD
    Comparison of the clinical syndromes of anti-GABAa versus anti-GABAb associated autoimmune encephalitis: A systematic review.
    J Neuroimmunol. 2021;363:577804.
    >> Share

  168. DIAS DA COSTA M, Leal Rato M, Cruz D, Valadas A, et al
    Longitudinally extensive transverse myelitis with anti-myelin oligodendrocyte glycoprotein antibodies following SARS-CoV-2 infection.
    J Neuroimmunol. 2021;361:577739.
    >> Share

  169. THOLANCE Y, Antoine JC, Mohr L, Jung M, et al
    Anti-FGFR3 antibody epitopes are functional sites and correlate with the neuropathy pattern.
    J Neuroimmunol. 2021;361:577757.
    >> Share

  170. TALBOT J, Hojsgaard Chow H, Holm Hansen R, von Essen MR, et al
    Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS.
    J Neuroimmunol. 2021;361:577756.
    >> Share

  171. REN H, Fan S, Zhao Y, Guan H, et al
    The changing spectrum of antibody-mediated encephalitis in China.
    J Neuroimmunol. 2021;361:577753.
    >> Share

  172. PUJARI SS, Kulkarni RV, Ojha P, Gursahani R, et al
    Acute haemorrhagic leukoencephalitis (AHLE) - our experience and a short review.
    J Neuroimmunol. 2021;361:577751.
    >> Share

  173. DIAS L, Barbosa L, Martins F, Braz L, et al
    Risk factors for idiopathic myelitis at admission and predictors for late diagnostic change.
    J Neuroimmunol. 2021;361:577747.
    >> Share

  174. SAHA S, Mukherjee S, Guha G, Mukhopadhyay D, et al
    Dynamics of AQP4 upon exposure to seropositive patient serum before and after Rituximab therapy in Neuromyelitis Optica: A cell-based study.
    J Neuroimmunol. 2021;361:577752.
    >> Share

  175. NAGIREDDY RBR, Kumar A, Singh VK, Prasad R, et al
    Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    J Neuroimmunol. 2021;361:577742.
    >> Share

  176. KESHVARI MK, van Someren F, Sheikh S, Galea I, et al
    Eosinophilia during natalizumab treatment: Incidence, risk factors and temporal patterns.
    J Neuroimmunol. 2021;361:577729.
    >> Share

  177. STECK AJ
    Anti-MAG neuropathy: From biology to clinical management.
    J Neuroimmunol. 2021;361:577725.
    >> Share

  178. ADAMEC I, Rogic D, Penz MG, Braun C, et al
    Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab.
    J Neuroimmunol. 2021;362:577788.
    >> Share

  179. SONG J, Yang J, Jing S, Yan C, et al
    Berberine attenuates experimental autoimmune myasthenia gravis via rebalancing the T cell subsets.
    J Neuroimmunol. 2021;362:577787.
    >> Share

  180. TOLJAN K, Amin M, Kunchok A, Ontaneda D, et al
    New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure.
    J Neuroimmunol. 2021;362:577785.
    >> Share

    November 2021
  181. CHEN B, Tian DS, Bu BT
    Immunological predictors for the outcome in patients with antibody-mediated autoimmune encephalitis.
    J Neuroimmunol. 2021;362:577779.
    >> Share

  182. CARAVAGNA C
    Comments on "Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine" by , J Neuroimmunol.
    J Neuroimmunol. 2021;362:577780.
    >> Share

  183. WUERCH E, Mishra M, Melo H, Ebacher V, et al
    Quantitative analysis of spinal cord neuropathology in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2021;362:577777.
    >> Share

  184. JIAO L, Li H, Guo S
    Eculizumab treatment for myasthenia gravis subgroups: 2021 update.
    J Neuroimmunol. 2021;362:577767.
    >> Share

  185. HWANG D, Boehm A, Rostami A, Zhang GX, et al
    Oral D-mannose treatment suppresses experimental autoimmune encephalomyelitis via induction of regulatory T cells.
    J Neuroimmunol. 2021;362:577778.
    >> Share

  186. HASSANSHAHI G, Noroozi Karimabad M, Jebali A
    The therapeutic effect of PEGlated nanoliposome of pistachio unsaturated oils and its efficacy to attenuate inflammation in multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial phase I.
    J Neuroimmunol. 2021;362:577768.
    >> Share

  187. FINSTERER J
    SARS-CoV-2 vaccinations may not only be complicated by GBS but also by distal small fibre neuropathy.
    J Neuroimmunol. 2021;360:577703.
    >> Share

  188. POURMOGHADDAS Z, Sadeghizadeh A, Tara SZ, Zandifar A, et al
    Longitudinally extensive transverse myelitis as a sign of multisystem inflammatory syndrome following COVID-19 infection: A pediatric case report.
    J Neuroimmunol. 2021;360:577704.
    >> Share

  189. MOLAZADEH N, Filippatou AG, Vasileiou ES, Levy M, et al
    Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2021;360:577702.
    >> Share

  190. FREEDMAN MS, Wojcik J, Holmberg KH, Fluck M, et al
    Pharmacodynamic biomarkers of long-term interferon beta-1a therapy in REFLEX and REFLEXION.
    J Neuroimmunol. 2021;360:577715.
    >> Share

  191. NILLES C, Poillon G, Deschamps L, Daval M, et al
    IgG4-related pachymeningitis and mastoiditis, associated with cerebral venous thrombosis: A case report.
    J Neuroimmunol. 2021;360:577717.
    >> Share

  192. PANDIT L, Malli C, D'Cunha A, Sudhir A, et al
    Overcoming the challenges in diagnosis of AQP4-IgG positive neuromyelitis optica spectrum disorders in resource poor settings using an indigenized and cost effective cell based assay.
    J Neuroimmunol. 2021;360:577706.
    >> Share

  193. PACHE F, Ringelstein M, Aktas O, Kleiter I, et al
    C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD.
    J Neuroimmunol. 2021;360:577699.
    >> Share

  194. MASCIA E, Clarelli F, Zauli A, Guaschino C, et al
    Burden of rare coding variants in an Italian cohort of familial multiple sclerosis.
    J Neuroimmunol. 2021;362:577760.
    >> Share

    October 2021
  195. VAKRAKOU AG, Tzanetakos D, Evangelopoulos ME, Fragoulis GE, et al
    IgG4-related autoimmune manifestations in Alemtuzumab-treated multiple sclerosis patients.
    J Neuroimmunol. 2021;361:577759.
    >> Share

  196. FUJIMORI J, Miyazawa K, Nakashima I
    Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.
    J Neuroimmunol. 2021;361:577755.
    >> Share

  197. ZELADA-RIOS L, Pacheco-Barrios K, Galecio-Castillo M, Yamunaque-Chunga C, et al
    Acute disseminated encephalomyelitis and COVID-19: A systematic synthesis of worldwide cases.
    J Neuroimmunol. 2021;359:577674.
    >> Share

  198. SRIWASTAVA S, Lisak RP
    Acetylcholine receptor antibodies in a patient with sensory neuropathy.
    J Neuroimmunol. 2021;359:577692.
    >> Share

  199. TANG H, Wang L, Zhou H, Hao X, et al
    Psychiatric symptoms as initial manifestation in neuromyelitis optica spectrum disorder without cortical lesions: A report of two cases.
    J Neuroimmunol. 2021;359:577693.
    >> Share

  200. GOI LDS, Altenhofen S, Nabinger DD, Bonan CD, et al
    Decreased convulsive threshold and memory loss after anti-NMDAR positive CSF injection in zebrafish.
    J Neuroimmunol. 2021;359:577689.
    >> Share

  201. OTA S, Kotani T, Matsuda S, Nishioka D, et al
    Initial serum GM-CSF levels are associated with the severity of cerebral small vessel disease in microscopic polyangiitis patients.
    J Neuroimmunol. 2021;359:577671.
    >> Share

  202. SANTIAGO JA, Babico M, Stitt G, Thomas CA, et al
    Low-dose intrathecal rituximab is a safe and potentially effective treatment for pediatric neuroimmunologic disorders.
    J Neuroimmunol. 2021;359:577687.
    >> Share

  203. ACHIRON A, Mandel M, Dreyer-Alster S, Harari G, et al
    Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study.
    J Neuroimmunol. 2021;361:577746.
    >> Share

  204. KIMURA A, Kato S, Takekoshi A, Yoshikura N, et al
    Autoimmune glial fibrillary acidic protein astrocytopathy resembling isolated central nervous system lymphomatoid granulomatosis.
    J Neuroimmunol. 2021;361:577748.
    >> Share

  205. CHE NN, Chen SY, Li X, Ma JJ, et al
    Autoimmune-mediated secondary-parkinsonism presented with micrographia and cognitive impairment.
    J Neuroimmunol. 2021;361:577738.
    >> Share

  206. SEGAL JP, Phillips S, Dubois RM, Silva JR, et al
    Weight bearing as a measure of disease progression in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2021;361:577730.
    >> Share

    September 2021
  207. OO WM, Giri P, de Souza A
    AstraZeneca COVID-19 vaccine and Guillain- Barre Syndrome in Tasmania: A causal link?
    J Neuroimmunol. 2021;360:577719.
    >> Share

  208. SAMUDRALWAR RD
    Commentary: The spectrum of neurological manifestations related to COVID-19 and vaccinations.
    J Neuroimmunol. 2021;358:577660.
    >> Share

  209. GHOSH R, Dubey S, Mandal A, Ray BK, et al
    Complex movement disorders in SARS-CoV-2 infection induced acute disseminated encephalomyelitis.
    J Neuroimmunol. 2021;358:577655.
    >> Share

  210. PAGENKOPF C, Sudmeyer M
    A case of longitudinally extensive transverse myelitis following vaccination against Covid-19.
    J Neuroimmunol. 2021;358:577606.
    >> Share

  211. SRIWASTAVA S, Kataria S, Srivastava S, Kazemlou S, et al
    Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis.
    J Neuroimmunol. 2021;360:577721.
    >> Share

  212. VAN LIEVERLOO GGA, Wieske L, van Schaik IN, Deijs M, et al
    Virus discovery in chronic inflammatory demyelinating polyneuropathy.
    J Neuroimmunol. 2021;358:577668.
    >> Share

  213. MORCH MT, Khorooshi R, Marczynska J, Dubik M, et al
    Mitochondria-A target for attenuation of astrocyte pathology.
    J Neuroimmunol. 2021;358:577657.
    >> Share

  214. SECHI E, Zarbo R, Biancu MA, Chessa P, et al
    Prolonged B-cell depletion after rituximab in AQP4-IgG-positive neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2021;358:577666.
    >> Share

  215. ZHAO X, Yang P
    Hydroxychloroquine alleviates the neurotoxicity induced by anti-ribosomal P antibodies.
    J Neuroimmunol. 2021;358:577648.
    >> Share

  216. BAEK SH, Kim B, Shin JY, Choi SJ, et al
    EBI2-expressing B cells in neuromyelitis optica spectrum disorder with AQP4-IgG: Association with acute attacks and serum cytokines.
    J Neuroimmunol. 2021;358:577637.
    >> Share

  217. GOMBOLAY GY, Gadde JA
    Aseptic meningitis and leptomeningeal enhancement associated with anti-MOG antibodies: A review.
    J Neuroimmunol. 2021;358:577653.
    >> Share

  218. XIAO J, Chen X, Shang K, Tang Y, et al
    Clinical, neuroradiological, diagnostic and prognostic profile of autoimmune glial fibrillary acidic protein astrocytopathy: A pooled analysis of 324 cases from published data and a single-center retrospective study.
    J Neuroimmunol. 2021;360:577718.
    >> Share

  219. PHILLIPS O, Tubre T, Lorenco H, Batish SD, et al
    Limbic encephalitis in a child with ovarian teratoma and influenza B. Case report and critical review of the history of autoimmune anti-N-methyl-d-aspartate receptor encephalitis.
    J Neuroimmunol. 2021;360:577716.
    >> Share

    August 2021
  220. HAYASHI F, Isobe N, Cossu D, Yokoyama K, et al
    Elevated mycobacterium avium subsp. paratuberculosis (MAP) antibody titer in Japanese multiple sclerosis.
    J Neuroimmunol. 2021;360:577701.
    >> Share

  221. FARSHBAFNADI M, Agah E, Rezaei N
    The second brain: The connection between gut microbiota composition and multiple sclerosis.
    J Neuroimmunol. 2021;360:577700.
    >> Share

  222. RIBES GARCIA S, Casanova Estruch B, Gomez Pajares F, Juan Blanco MA, et al
    Prognostic utility of the IgM oligoclonal bands against myelin lipids in multiple sclerosis.
    J Neuroimmunol. 2021;359:577698.
    >> Share

  223. BRAINER-LIMA JPM, Leite BHS, de Araujo CMCS, Dhalia R, et al
    Are Zika virus cross-reactive antibodies against aquaporin-4 associated to Neuromyelitis Optica Spectrum Disorder?
    J Neuroimmunol. 2021;360:577697.
    >> Share

  224. HABEK M, Jakob Brecl G, Basic Kes V, Rogic D, et al
    Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study.
    J Neuroimmunol. 2021;359:577696.
    >> Share

  225. QIAO X, Wang H, Lu L, Chen J, et al
    Hippocampal microglia CD40 mediates NPSLE cognitive dysfunction in mice.
    J Neuroimmunol. 2021;357:577620.
    >> Share

  226. CHAKRABORTY AP, Pandit A, Ray BK, Mukherjee A, et al
    Capgras syndrome and confabulation unfurling anti NMDAR encephalitis with classical papillary thyroid carcinoma: First reported case.
    J Neuroimmunol. 2021;357:577611.
    >> Share

  227. EQUIZA J, Rodriguez-Antiguedad J, Campo-Caballero D, Iruzubieta P, et al
    Autoimmune GFAP astrocytopathy presenting with remarkable CNS hyperexcitability and oculogyric crises.
    J Neuroimmunol. 2021;359:577695.
    >> Share

  228. COSSU D, Yokoyama K, Sato S, Noda S, et al
    PARKIN modifies peripheral immune response and increases neuroinflammation in active experimental autoimmune encephalomyelitis (EAE).
    J Neuroimmunol. 2021;359:577694.
    >> Share

  229. MIN YG, Ju W, Ha YE, Ban JJ, et al
    Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature.
    J Neuroimmunol. 2021;359:577691.
    >> Share

  230. HAHAM N, Vaknin-Dembinsky A
    COVID-19 in Cladribine-treated patient with multiple sclerosis.
    J Neuroimmunol. 2021;359:577690.
    >> Share

    July 2021
  231. KRAUS EE, Kakuk-Atkins L, Farinas MF, Jeffers M, et al
    Regulation of autoreactive CD4 T cells by FoxO1 signaling in CNS autoimmunity.
    J Neuroimmunol. 2021;359:577675.
    >> Share

  232. LOVETT-RACKE AE, Yang Y, Liu Y, Gormley M, et al
    B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report.
    J Neuroimmunol. 2021;359:577676.
    >> Share

  233. LAI QL, Cai MT, Zheng Y, Zhang TY, et al
    Seasonal variation in autoimmune encephalitis: A multi-center retrospective study.
    J Neuroimmunol. 2021;359:577673.
    >> Share

  234. YAO Y, Li X, Lin J, Zhang X, et al
    Thymoma-associated autoimmune encephalitis with positive Titin antibodies: A case report.
    J Neuroimmunol. 2021;358:577670.
    >> Share

  235. GUO L, Ren H, Fan S, Guan H, et al
    Autoantibody against the Rab6A/Rab6B in primary autoimmune cerebellar ataxia associated with Sjogren's syndrome: A case report.
    J Neuroimmunol. 2021;359:577667.
    >> Share

  236. WANG J, Yan C, Zhao Z, Chen H, et al
    Sexual dysfunction in patients with myasthenia gravis.
    J Neuroimmunol. 2021;358:577669.
    >> Share

  237. CAPARO-ZAMALLOA C, Alvarez-Toledo K, Yamunaque-Chunga C, Castro-Suarez S, et al
    Autoimmune neurology: Co-occurrence of anti-NMDAR encephalitis and anti-MOG associated disease, report of a case.
    J Neuroimmunol. 2021;358:577663.
    >> Share

  238. LOCKHART A, Boers P
    Paraneoplastic neurologic syndromes with multiple neural autoantibodies: A report of two cases.
    J Neuroimmunol. 2021;358:577665.
    >> Share

  239. LI R, Wang J, Li C, Liu X, et al
    Rescue immunoadsorption treatment for neuromyelitis optica spectrum disorder attacks unresponsive to intravenous methylprednisolone.
    J Neuroimmunol. 2021;356:577604.
    >> Share

  240. DINOTO A, Cheli M, Bratina A, Sartori A, et al
    Bortezomib in anti-N-Methyl-d-Aspartate-Receptor (NMDA-R) encephalitis: A systematic review.
    J Neuroimmunol. 2021;356:577586.
    >> Share

  241. NARESH K, Miraclin TA, Prabhakar AT, Mathew V, et al
    Epstein-Barr virus infection in a woman with aquaporin-4 seropositive neuromyelitis optica.
    J Neuroimmunol. 2021;356:577581.
    >> Share

  242. WONG CK, Hor JY, Loo YP, Heng HS, et al
    High incidence of NMDAR encephalitis among Austronesians: A population-based study in Sabah, Malaysia.
    J Neuroimmunol. 2021;356:577584.
    >> Share

  243. HONGO Y, Kaida K, Komuta Y, Takazaki H, et al
    Cholesterol-added antigens can enhance antiglycolipid antibody activity: Application to antibody testing.
    J Neuroimmunol. 2021;356:577580.
    >> Share

  244. NISHRI Y, Fainstein N, Goldfarb S, Hampton D, et al
    Modeling compartmentalized chronic immune-mediated demyelinating CNS disease in the Biozzi ABH mouse.
    J Neuroimmunol. 2021;356:577582.
    >> Share

  245. MIMPEN M, Damoiseaux J, van Doorn W, Rolf L, et al
    Proportions of circulating transitional B cells associate with MRI activity in interferon beta-treated multiple sclerosis patients.
    J Neuroimmunol. 2021;358:577664.
    >> Share

  246. CORTES-VICENTE E, Alvarez-Velasco R, Illa I, Gallardo E, et al
    Comment to "Autoantibodies to cortactin and agrin in sera of patients with myasthenia gravis".
    J Neuroimmunol. 2021;358:577659.
    >> Share

  247. IVANOVA M, Voronkova A, Sukhorukov V, Zakharova M, et al
    Different neuroinflammatory gene expression profiles in highly active and benign multiple sclerosis.
    J Neuroimmunol. 2021;358:577650.
    >> Share

  248. KHANMOHAMMADI S, Malekpour M, Jabbari P, Rezaei N, et al
    Genetic basis of Guillain-Barre syndrome.
    J Neuroimmunol. 2021;358:577651.
    >> Share

    June 2021
  249. MOSTAFA GA, Meguid NA, Shehab AAS, Elsaeid A, et al
    Plasma levels of nerve growth factor in Egyptian autistic children: Relation to hyperserotonemia and autoimmunity.
    J Neuroimmunol. 2021;358:577638.
    >> Share

  250. MIRZAEI R, Zamani F, Hajibaba M, Rasouli-Saravani A, et al
    The pathogenic, therapeutic and diagnostic role of exosomal microrna in the autoimmune diseases.
    J Neuroimmunol. 2021;358:577640.
    >> Share

  251. JAKHMOLA S, Upadhyay A, Jain K, Mishra A, et al
    Herpesviruses and the hidden links to Multiple Sclerosis neuropathology.
    J Neuroimmunol. 2021;358:577636.
    >> Share

  252. UZAWA A, Akamine H, Kojima Y, Ozawa Y, et al
    High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis.
    J Neuroimmunol. 2021;358:577634.
    >> Share

  253. FINSTERER J
    Steroid-responsive, transverse myelitis is a known complication of COVID-19.
    J Neuroimmunol. 2021;355:577566.
    >> Share

  254. LEE JK, Kwon S, Han JH, Yoon SE, et al
    Increased proportion of CD20+ T cells after rituximab treatment in patient with neuromyelitis optica later diagnosed with lung B-cell lymphoma: A case report.
    J Neuroimmunol. 2021;355:577564.
    >> Share

  255. GOVIL-DALELA T, Datta I, Williams M
    Refractory NMDA-receptor encephalitis in a teenager: A novel use of Bortezomib.
    J Neuroimmunol. 2021;355:577565.
    >> Share

  256. SON H, Lee WJ, Moon J, Yoon S, et al
    Isolated CNS involvement in eosinophilic granulomatosis with polyangiitis treated with mepolizumab: A case report.
    J Neuroimmunol. 2021;355:577551.
    >> Share

  257. REYES S, Cunningham AL, Kalincik T, Havrdova EK, et al
    Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.
    J Neuroimmunol. 2021;357:577627.
    >> Share

  258. FINSTERER J, Ghosh R
    Dimensions of SARS-CoV-2 associated Guillain-Barre syndrome.
    J Neuroimmunol. 2021;357:577626.
    >> Share

  259. NIINO M, Fukazawa T, Miyazaki Y, Ura S, et al
    Seasonal fluctuations in serum levels of vitamin D in Japanese patients with multiple sclerosis.
    J Neuroimmunol. 2021;357:577624.
    >> Share

    May 2021
  260. GRISANTI SG, Franciotta D, Garnero M, Zuppa A, et al
    A case series of parainfectious Guillain-Barre syndrome linked to influenza A (H1N1) virus infection.
    J Neuroimmunol. 2021;357:577605.
    >> Share

  261. MANOUCHEHRI N, Guisso DR, Hussain RZ, Minassian BA, et al
    The antioxidant MnTBAP does not effectively downregulate CD4 expression in T cells in vivo.
    J Neuroimmunol. 2021;354:577544.
    >> Share

  262. WANG T, Wang B, Zeng Z, Li H, et al
    Efficacy and safety of bortezomib in rituximab-resistant anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis as well as the clinical characteristics: An observational study.
    J Neuroimmunol. 2021;354:577527.
    >> Share

  263. FINSTERER J, Scorza FA, Scorza CA, Fiorini AC, et al
    Diagnosing SARS-CoV-2 associated Guillain-Barre syndrome requires cerebro-spinal-fluid studies.
    J Neuroimmunol. 2021;357:577609.
    >> Share

  264. SVIRIDOVA A, Rogovskii V, Kudrin V, Pashenkov M, et al
    The role of 5-HT2B-receptors in fluoxetine-mediated modulation of Th17- and Th1-cells in multiple sclerosis.
    J Neuroimmunol. 2021;356:577608.
    >> Share

  265. ROTOLO RA, Demuro J, Drummond G, Little C, et al
    Prophylactic exposure to oral riluzole reduces the clinical severity and immune-related biomarkers of experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2021;356:577603.
    >> Share

  266. SOLTANMORADI S, Tavakolpour V, Moghadasi AN, Kouhkan F, et al
    Expression analysis of NF-kappaB-associated long noncoding RNAs in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients.
    J Neuroimmunol. 2021;356:577602.
    >> Share

  267. KELLY H, Sokola B, Abboud H
    Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients.
    J Neuroimmunol. 2021;356:577599.
    >> Share

  268. ZULIANI L, Marangoni S, De Gaspari P, Rosellini I, et al
    Epidemiology of neuronal surface antibody-mediated autoimmune encephalitis and antibody-based diagnostics.
    J Neuroimmunol. 2021 May 1:577598. doi: 10.1016/j.jneuroim.2021.577598.
    >> Share

    April 2021
  269. YOKOTE H
    Author's response in reply to "Question about data: Importance of serum amyloid A level in patients with multiple sclerosis".
    J Neuroimmunol. 2021;356:577589.
    >> Share

  270. DOPPLER K, Hemprich A, Haarmann A, Brecht I, et al
    Autoantibodies to cortactin and agrin in sera of patients with myasthenia gravis.
    J Neuroimmunol. 2021;356:577588.
    >> Share

  271. GARCIA-MANTEIGA JM, Clarelli F, Bonfiglio S, Mascia E, et al
    Identification of differential DNA methylation associated with multiple sclerosis: A family-based study.
    J Neuroimmunol. 2021;356:577600.
    >> Share

  272. MASI G, Spagni G, Campetella L, Monte G, et al
    Assessing the role of a tissue-based assay in the diagnostic algorithm of autoimmune encephalitis.
    J Neuroimmunol. 2021;356:577601.
    >> Share

  273. PAPRI N, Hayat S, Mohammed A, Afsar MNA, et al
    Guillain-Barre syndrome associated with SARS-CoV-2 infection: A case report with long term follow up.
    J Neuroimmunol. 2021;356:577590.
    >> Share

  274. HOU H, Sun Y, Miao J, Gao M, et al
    Ponesimod modulates the Th1/Th17/Treg cell balance and ameliorates disease in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2021;356:577583.
    >> Share

  275. SHEIKH AB, Chourasia PK, Javed N, Chourasia MK, et al
    Association of Guillain-Barre syndrome with COVID-19 infection: An updated systematic review.
    J Neuroimmunol. 2021;355:577577.
    >> Share

  276. WANG J, Qiu Z, Li D, Dong H, et al
    Anti-contactin-associated protein-like 2 antibody-associated cerebellar ataxia: A case report and literature review.
    J Neuroimmunol. 2021;353:577515.
    >> Share

  277. ZHANG H, Yang Y, Luo X
    Anti-MOG antibodies associated demyelination following encephalomeningitis: Case report.
    J Neuroimmunol. 2021;353:577519.
    >> Share

  278. LI C, Wang J, Sun X, Li R, et al
    The current situation of diagnosis and treatment of neuromyelitis optica spectrum disorder: Experience with 461 cases from a single centre in South China.
    J Neuroimmunol. 2021;353:577506.
    >> Share

  279. DIEM L, Hoepner R, Bagnoud M, Salmen A, et al
    Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature.
    J Neuroimmunol. 2021;353:577505.
    >> Share

  280. FANG F, Wang Y, Xu W
    Anti-N-methyl-d-aspartate receptor encephalitis associated with intracranial cryptococcal infection: A case report and 2-year follow-up.
    J Neuroimmunol. 2021;353:577502.
    >> Share

  281. DU Q, Shi Z, Chen H, Zhang Y, et al
    Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2021;353:577494.
    >> Share

  282. PRADO MB JR, Narito KM, Adiao KJB
    Anti-GM1 IgM antibody positive axonal variant of Guillain-Barre-syndrome in a pediatric patient with dengue fever.
    J Neuroimmunol. 2021;355:577572.
    >> Share

  283. FAN Z, Zheng D, Wen X, Shen F, et al
    CYP3A5*3 polymorphism and age affect tacrolimus blood trough concentration in myasthenia gravis patients.
    J Neuroimmunol. 2021;355:577571.
    >> Share

  284. DINIZ SN, da Silva CF, de Almeida IT, da Silva Costa FE, et al
    INFbeta treatment affects global DNA methylation in monocytes of patients with multiple sclerosis.
    J Neuroimmunol. 2021;355:577563.
    >> Share

    March 2021
  285. DINOTO A, Bosco A, Sartori A, Bratina A, et al
    Hiccups, severe vomiting and longitudinally extensive transverse myelitis in a patient with prostatic adenocarcinoma and Aquaporin-4 antibodies.
    J Neuroimmunol. 2021;352:577488.
    >> Share

  286. LI X, Hou C, Wu WL, Liang H, et al
    Pediatric anti-N-methyl-d-aspartate receptor encephalitis in southern China: Analysis of 111 cases.
    J Neuroimmunol. 2021;352:577479.
    >> Share

  287. DAY GS, Gordon BA, Bucelli RC, Perrin RJ, et al
    Leveraging molecular biomarkers to make the common diagnosis in the uncommon patient.
    J Neuroimmunol. 2021;352:577474.
    >> Share

  288. COSSU D, Yokoyama K, Sakanishi T, Kuwahara-Arai K, et al
    A mucosal immune response induced by oral administration of heat-killed Mycobacterium avium subsp. paratuberculosis exacerbates EAE.
    J Neuroimmunol. 2021;352:577477.
    >> Share

  289. CHAUDHARY P, Marracci GH, Calkins E, Pocius E, et al
    Thyroid hormone and thyromimetics inhibit myelin and axonal degeneration and oligodendrocyte loss in EAE.
    J Neuroimmunol. 2021;352:577468.
    >> Share

    February 2021
  290. AKAISHI T, Misu T, Takahashi T, Takai Y, et al
    Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders.
    J Neuroimmunol. 2021;351:577467.
    >> Share

  291. CHOUDHARY A, Bhargava A, Khichar S, Pradhan S, et al
    Etiological spectrum, clinico-radiological profile and treatment outcomes of longitudinally extensive transverse myelitis - A prospective study from Northwest India.
    J Neuroimmunol. 2021;351:577456.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016